When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and ...
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...
Please provide your email address to receive an email when new articles are posted on . The positive phase 3 results of the MAPLE-HCM trial of aficamten vs. metoprolol for obstructive HCM were ...
EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure -- ...
Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Gene defect that affects a protein found in the heart muscle ...
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small ...
Hypertrophic cardiomyopathy (HCM) is a genetic condition that results in the thickening of the muscle walls in the left ventricle of the heart. In HCM, muscles in the walls of the heart may become ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results